Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Deciphera Pharmaceuticals, LLC

Status: Enrolling

Conditions: Tenosynovial Giant Cell Tumor

Study type: Observational

Funder types: Industry

Identifiers

NCT07075471

DCC-3014-04-001

Details and patient eligibility

About

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.

This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Diagnosis of TGCT according to medical records
2. Prescribed vimseltinib per the approved label requirements. Participants are eligible if either (A) the decision to receive vimseltinib has been made but treatment has not yet been initiated or (B) the decision to receive vimseltinib has been made and participant has received first dose of prescribed vimseltinib less than 6 months prior to study enrollment
3. Has provided informed consent and medical records release

Exclusion criteria

1. Participant has received any other systemic agent for the treatment of TGCT during the 6 months prior to starting treatment with vimseltinib
2. Participant has received the first dose of prescribed vimseltinib in the current treatment course more than 6 months before study enrollment
3. Participant is active in an interventional clinical trial of vimseltinib